MD, FRCP(C)
Professor of Psychiatry and Pharmacology,
University of Toronto
Head, Mood Disorders Psychopharmacology Unit,
University Health Network
Program Clinical Director, Mental Health and Addictions,
The Royal Victoria Regional Health Centre
Toronto, ON
Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto. Dr. McIntyre was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022 and 2023 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre has authored/co-authored more than 1100 peer-reviewed articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders.
Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders. Dr. McIntyre has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders. Dr. McIntyre’s research has also extended into public health and implementation research at the population-based level.
Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada. Additionally, Dr. McIntyre was awarded the Colvin Prize for Outstanding Achievement in Mood Disorders Research from the Brain and Behavior Research Foundation in 2023.
Dr. McIntyre has also contributed extensively to clinical practice guidelines. For example, Dr. McIntyre is the lead author of the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder. In addition, Dr. McIntyre is also the lead author of the International Expert Opinion on the Available Evidence and Implementation of Ketamine and Esketamine in Mood Disorders. Dr. McIntyre is also a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders as well as the Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for Mood Disorders.
Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
MD, FRCPC
Professor, Department of Psychiatry and Behavioural Neurosciences,
McMaster University
Hamilton, ON
Dr. Michael Van Ameringen is a Professor in the Department of Psychiatry and Behavioural Neurosciences at McMaster University. His current research is focused on the psychopharmacology of Anxiety and Mood Disorders, Obsessive-Compulsive and Related Disorders, ADHD, treatment resistance and the use of psychedelics and GLP-1 receptor agonists in psychiatric disorders. Other research interests include the use of medical cannabis for anxiety and related disorders and problematic Internet use.
He is the Anxiety Lead for The Canadian Network for Mood and Anxiety Treatments (CANMAT). He is the lead author in the 2025 CANMAT-ICOCS International Guidelines for the treatment of OCD. He was also a member of the Steering Committee for the Canadian Anxiety Disorder Treatment Guidelines, and the World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders; and a co-author of the 2023 CANMAT Depression guidelines. He recently co-authored the CANMAT Task Force Report on Serotonergic Psychedelic Treatments for Major Depressive Disorder.
Dr. Van Ameringen is Co-Chair of the Obsessive-Compulsive Research Network of the European College of Neuropsychopharmacology (ECNP), and a member of the Scientific Council of the Anxiety and Depression Association of America. He is the Associate Editor for the International Journal of Psychiatry in Clinical Practice and is on the editorial board for the Journal of Mood and Anxiety, Journal of Psychiatric Research and Comprehensive Psychiatry.
He is also an associate faculty member of the Michael G. DeGroote Centre for Medicinal Cannabis Research and is the Director of the ADHD Fellowship Program in the Department of Psychiatry and Behavioural Neurosciences at McMaster University. Dr. Van Ameringen has published widely in the area of OCD, ADHD and Anxiety Disorders.
MD
Staff Psychiatrist, Clinician Scientist
Medical Head, Ambulatory Services, Lead Psychiatrist, Partial Hospital Program
Schizophrenia Program, Centre for Addiction and Mental Health (CAMH), University of Toronto
Associate Professor, Department of Psychiatry, Faculty of Medicine, University of Toronto
Associate Member, Institute of Medical Science (IMS), University of Toronto
Toronto, ON
Dr. Ofer Agid is staff psychiatrist and a clinician scientist in the Schizophrenia Program at the Centre for Addiction and Mental Health in Toronto. Dr. Agid is the Medical Head, Ambulatory Services and the Lead Psychiatrist, Partial Hospital Program at the Schizophrenia Program. He is also Associate Professor in the Department of Psychiatry, Faculty of Medicine, University of Toronto and Associate Member, Institute of Medical Science (IMS), University of Toronto.
Areas of Research
Dr. Agid’s research focus is psychopharmacology in schizophrenia, specifically early response to antipsychotic medications, early predictors of response and treatment resistant schizophrenia. His work has uncovered a new “early onset of action” hypothesis of antipsychotics, which has impacted current practice guidelines for the treatment of schizophrenia.
As the medical leader in the First-Episode Schizophrenia program, Dr. Agid initiated an algorithm-based treatment approach for first-episode schizophrenia while collecting extensive clinical data regarding treatment response. This algorithm was implemented to optimize antipsychotic treatment during the earliest stages of the illness, a critical time period in terms of longer-term outcomes. This systematic and standardized approach has resulted in a large and comprehensive database; the published data to date have provided clear, empiric evidence that clinicians can use in approaching the pharmacological management of first-episode schizophrenia. It has also challenged current practice patterns and proven valuable in examining trajectories of response.
In addition, Dr. Agid is involved in investigating patterns of non-adherence and placebo response, treatment resistant schizophrenia, psychopharmacological mechanism of action of antipsychotics using brain imaging techniques and examining value systems and happiness in schizophrenia with an emphasis on the relationship to, and influence on, motivation and functional outcomes.
Dr. Agid is a recipient of numerous grants. He presented his research at major meetings and conferences and has published in major psychiatry journals.
MD, FRCPC
General Psychiatrist and Local Head of Department, Royal Columbian Hospital
Regional Division Head of Adult Psychiatry, Fraser Health
New Westminster, BC
Dr. Casey graduated from UBC medical school and residency. She is a general psychiatrist at Royal Columbian Hospital in New Westminster, BC. She practices inpatient, outpatient, and community psychiatry. She is the local department head at her hospital and the regional division head of adult psychiatry for Fraser Health. She is very involved in teaching and has taught hundreds of medical students and residents.
MD, CM, MSc, FRCPC
Director, PEPP-MUHC (program for the evaluation and prevention of psychosis)
Director, Schizophrenia program, MUHC
Associate Professor, Department of Psychiatry, McGill University
Dr. Margolese is an Associate Professor in the Department of Psychiatry of McGill University. He is currently the program director of the McGill Clinical Pharmacology and Toxicology residency program. He is director of the PEPP first episode psychosis and Schizophrenia programs at the McGill University Health Centre and director of the Clinical Psychopharmacology and Therapeutics Unit.
He has given numerous lectures and presentations both nationally and internationally and has published over 75 articles. He is vice-president of research and a founding member of the Canadian Consortium for Early Intervention in Psychosis.
In his clinical work, Dr. Margolese specializes in psychopharmacology consultations, first episode psychosis, and treatment resistant schizophrenia.
Professor
Dr. Paul Janssen Chair in Psychotic Disorders
Director of Research, Department of Psychiatry, Dalhousie University
Clinical Director, Early Psychosis Intervention Nova Scotia
Nova Scotia Health
Dr. Tibbo received his B.Sc. (Hons) from Mount Alison University in Sackville, NB, and his MD from Memorial University of Newfoundland. He completed his residency in psychiatry at the University of Alberta and following this joined the staff at the University of Alberta Hospital as a clinician and researcher. He was instrumental in the development of and co-directed both the Bebensee Schizophrenia Research Unit and the Edmonton Early Psychosis Intervention Clinic.
In 2008 Dr. Tibbo was named the first Dr. Paul Janssen Chair in Psychotic Disorders, an endowed research chair, at Dalhousie University in Halifax NS. He is a Professor in the Department of Psychiatry with a cross-appointment in Psychology and Neuroscience at Dalhousie University. He is Director of Research for the Department of Psychiatry at Dalhousie and Clinical Director of the provincial Early Psychosis Intervention Nova Scotia (EPINS) program for Nova Scotia Health. Dr Tibbo is President of the Canadian Consortium for Early Intervention in Psychosis (CCEIP), helping to advance early intervention care at the national level.
Dr. Tibbo’s publications are primarily in the area of schizophrenia with his current foci of study including individuals at the early phase of, and at risk for, a psychotic illness. Dr. Tibbo’s areas of research include application of in vivo brain neuroimaging techniques to study psychosis as well as research interests in co-morbidities in schizophrenia (primarily substance misuse and psychosis), pathways to care/service delivery, education, and non-pharmacological treatment options. He is funded by local and national peer reviewed funding agencies and well published in leading journals. Dr Tibbo was a recipient of the Canadian Alliance on Mental Illness and Mental Health’s Champion of Mental Health Research award in 2017 and the 2018 Royal College of Physicians and Surgeons of Canada Prix d’Excellence - Specialist of the Year (region 5).
Dr. Atul Khullar is a psychiatrist and sleep specialist who focuses on the integrative management of obesity, sleep, mood/anxiety and attention deficit disorders in age groups from adolescence onwards. Recently, he has gained expertise in the selective use of ketamine for resistant mood disorders.
He completed his medical school and residency at the University of Alberta, and a sleep and mood/anxiety disorders fellowship at the University of Toronto. He has additional pediatric sleep medicine training from the University of Pennsylvania.
Dr. Khullar is board-certified in Psychiatry and Sleep Medicine in both Canada and the United States. He is also a fellow of the American Academy of Sleep Medicine, Diplomate of the American Board of Obesity Medicine, and a Clinical Associate Professor at the University of Alberta.
Actively involved in research and education, Dr. Khullar has given more than 600 invited presentations to public and professional audiences worldwide. He has published a number of articles and chapters as well as chaired more than 20 national CME programs in his specialized areas.
Currently, he is the medical director of the Northern Alberta Sleep Clinic in Edmonton. Dr. Khullar is also a senior consultant for the Grey Nuns Hospital, the Edmonton Oilers, the Newly Institute and MedSleep, a Canada-wide network of community sleep clinics. He has also worked with the Canadian Winter Olympic team in the past.
Professor of Neurology, Department of Clinical Neurological Sciences
Western University, London, Ontario
Received MD from Western University, where I also did training in Internal Medicine and Neurology, receiving my fellowship in Neurology from the Royal College of Physicians and Surgeons of Canada.
I did a Medical Research Council of Canada sponsored research fellowship with Professor Joseph Martin at Harvard Medical School and the Massachusetts General Hospital in Boston and then returned to Western University in London Ontario.
Professor of Neurology in the Department of Clinical Neurological Sciences.
After doing General Neurology with a special interest in Neuroendocrinology for 39 years, I now limit my practice to headache Neurology.
MBBS, FRCPC
Director, UBC Headache Clinic
Associate Clinical Professor, Neurology
University of British Columbia
Dr. Spacey is a Neurologist and Clinical Associate Professor in the Division of Neurology at UBC. She completed a residency in Neurology at UBC and a fellowship in Neurogenetics at Queen Square, London England. She is Director of the UBC Headache Clinic and UBC Neurogenetics Clinic. She is past president of the Canadian Headache Society and Director of the UBC Clinician Investigator Program. She lectures nationally and internationally. Her research interest and publications are in the field of calcium channels and the pathogenesis and molecular genetics of migraine.
BSc MSc MD FRCPC, Pain Psychiatrist
Clinical Assistant Professor, University of British Columbia
Director, UBC Pain Medicine Residency Program
Dr. Michael Butterfield is a Clinical Assistant Professor at UBC with appointments in the Departments of Psychiatry and Anesthesiology, Pharmacology & Therapeutics. He has a keen interest in medical education and has been the Director of the UBC Pain Medicine Residency Program for 5 years. He practices clinically at various tertiary pain clinics and the UBC Headache Clinic. He is a member of several national committees in the areas of pain medicine and psychiatry and was recently awarded the Early Career Achievement in Psychiatry Award by the Canadian Psychiatric Association.
Message